Serum cytokeratin 18 as a biomarker for gastric cancer

Clinical and Experimental Medicine

Volumn 13, Issue 4, 2013, Pages 289-295

  Oyama, Katsunobu ^a   Fushida, Sachio ^a   Kinoshita, Jun ^a   Okamoto, Koichi ^a   Makino, Isamu ^a   Nakamura, Keishi ^a   Hayashi, Hironori ^a   Inokuchi, Masafumi ^a   Nakagawara, Hisatoshi ^a   Tajima, Hidehiro ^a   Fujita, Hideto ^a   Takamura, Hiroyuki ^a   Ninomiya, Itasu ^a   Kitagawa, Hirohisa ^a   Fujimura, Takashi ^a   Ohta, Tetsuo ^a  

^a KANAZAWA UNIVERSITY   (Japan)

Author keywords

Biomarker; Cytokeratin 18; Gastric cancer; Serum M30 level; Serum M65 level

Indexed keywords

BIOLOGICAL MARKER; CA 19-9 ANTIGEN; CARCINOEMBRYONIC ANTIGEN; CYTOKERATIN 18; M30 PROTEIN; M65 PROTEIN; MONOCLONAL ANTIBODY; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CANCER STAGING; CELL DEATH; CLINICAL FEATURE; CONTROLLED STUDY; CORRELATION ANALYSIS; DIAGNOSTIC VALUE; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGNOSIS; PROTEIN BLOOD LEVEL; PROTEIN DETERMINATION; SENSITIVITY AND SPECIFICITY; STOMACH CANCER;

ADULT; AGED; BIOLOGICAL MARKERS; CLINICAL LABORATORY TECHNIQUES; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; KERATIN-18; MALE; MIDDLE AGED; SENSITIVITY AND SPECIFICITY; SERUM; STOMACH NEOPLASMS;

EID: 84888380277     PISSN: 15918890     EISSN: 15919528     Source Type: Journal    
DOI: 10.1007/s10238-012-0202-9     Document Type: Article

References (31)

1. Srivastava S, Srivastava RG (2005) Proteomics in the forefront of cancer biomarker discovery. J Proteome Res 13:1098-1103 (Pubitemid 41208667)
2. Scott LC, Evans TR, Cassidy J, Harden S, Paul J, Ullah R et al (2009) Cytokeratin 18 in plasma of patients with gastrointestinal adenocarcinoma as a biomarker of tumour response. Br J Cancer 101:410-417
3. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Murray T et al (2008) Cancer statistics. 2008. CA Cancer J Clin 58:71-96 (Pubitemid 351521864)
4. Holdenrieder S, Stieber P, Bodenmüller H, Busch M, Fertig G, Fürst H et al (2001) Nucleosomes in serum of patients with benign and malignant diseases. Int J Cancer 95:114-120 (Pubitemid 32187083)
5. Roth GA, Krenn C, Brunner M, Moser B, Ploder M, Spittler A et al (2004) Elevated serum levels of epithelial cell apoptosis-specific cytokeratin 18 neoepitope m30 in critically ill patients. Shock 22:218-220 (Pubitemid 39468985)
6. Holdenrieder S, Stieber P, VON Pawel J, Raith H, Nagel D, Feldmann K et al (2006) Early and specific prediction of the therapeutic efficacy in non-small cell lung cancer patients by nucleosomal DNA and cytokeratin-19 fragments. Ann N Y Acad Sci 1075:244-257 (Pubitemid 44532791)
7. Pichon MF, Labroquère M, Rezaï K, Lokiec F (2006) Variations of soluble fas and cytokeratin 18-Asp 396 neo-epitope in different cancers during chemotherapy. Anticancer Res 26:2387-2392 (Pubitemid 43980206)
8. Barczyk K, Kreuter M, Pryjma J, Booy EP, Maddika S, Ghavami S et al (2005) Serum cytochrome c indicates in vivo apoptosis and can serve as a prognostic marker during cancer therapy. Int J Cancer 116:167-173 (Pubitemid 40967251)
9. Neuber K, Eidam B (2006) Expression of Fas ligand (CD95L) in primary malignant melanoma and melanoma metastases is associated with overall survival. Onkologie 29:361-365 (Pubitemid 44370804)
10. Chou CF, Riopel CL, Rott LS, Omary MB (1993) A significant soluble keratin fraction in 'simple' epithelial cells. Lack of an apparent phosphorylation and glycosylation role in keratin solubility. J Cell Sci 105:433-444 (Pubitemid 23234162)
11. Lane EB, Alexander CM (1990) Use of keratin antibodies in tumor diagnosis. Semin Cancer Biol 1:165-179
12. Abe T, Fukumoto M, Tsuchiya K, Kuramochi K, Furuta T, Togoh S et al (1989) Human monoclonal antibodies against cytokeratin 18 generated from patients with gastric cancer. Jpn J Cancer Res 80:271-276 (Pubitemid 20027220)
13. Xu W, Zhang MW, Huang J, Wang X, Xu SF, Li Y et al (2005) Correlation between CK18 gene and gastric carcinoma micrometastasis. World J Gastroenterol 11:6530-6534 (Pubitemid 43136894)
14. Sheard MA, Vojtesek B, Simickova M, Valik D (2002) Release of cytokeratin-18 and -19 fragments (TPS and CYFRA 21-1) into the extracellular space during apoptosis. J Cell Biochem 85:670-677 (Pubitemid 34462778)
15. Kramer G, Erdal H, Mertens HJ, Nap M, Mauermann J, Steiner G et al (2004) Differentiation between cell death modes using measurements of different soluble forms of extracellular cytokeratin 18. Cancer Res 64:1751-1756 (Pubitemid 38428698)
16. Galluzzi L, Maiuri MC, Vitale I, Zischka H, Castedo M, Zitvogel L et al (2007) Cell death modalities: classification and pathophysiological implications. Cell Death Differ 14:1237-1243 (Pubitemid 46969863)
17. Caulín C, Salvesen GS, Oshima RG (1997) Caspase cleavage of keratin 18 and reorganization of intermediate filaments during epithelial cell apoptosis. J Cell Biol 138:1379-1394 (Pubitemid 27415063)
18. Kramer G, Schwarz S, Hägg M, Havelka AM, Linder S (2006) Docetaxel induces apoptosis in hormone refractory prostate carcinomas during multiple treatment cycles. Br J Cancer 94:1592-1598 (Pubitemid 43924919)
19. Ulukaya E, Yilmaztepe A, Akgoz S, Linder S, Karadag M (2007) The levels of caspase-cleaved cytokeratin 18 are elevated in serum from patients with lung cancer and helpful to predict the survival. Lung Cancer 56:399-404 (Pubitemid 46679086)
20. Ueno T, Toi M, Bivén K, Bando H, Ogawa T, Linder S (2003) Measurement of an apoptotic product in the sera of breast cancer patients. Eur J Cancer 39:769-774 (Pubitemid 36315993)
21. de Haas EC, di Pietro A, Simpson KL, Meijer C, Suurmeijer AJ, Lancashire LJ et al (2008) Clinical evaluation of M30 and M65 ELISA cell death assays as circulating biomarkers in a drug-sensitive tumor, testicular cancer. Neoplasia 10:1041-1048
22. Koelink PJ, Lamers CB, Hommes DW, Verspaget HW (2009) Circulating cell death products predict clinical outcome of colorectal cancer patients. BMC Cancer 9:88
23. Wu YX, Wang JH, Wang H, Yang XY (2003) Study on expression of Ki-67, early apoptotic protein M30 in endometrial carcinoma and their correlation with prognosis. Zhonghua Bing Li Xue Za Zhi 32:314-318
24. Dive C, Smith RA, Garner E, Ward T, George-Smith SS, Campbell F et al (2010) Considerations for the use of plasma cytokeratin 18 as a biomarker in pancreatic cancer. Br J Cancer 102:577-582
25. Brandt D, Volkmann X, Anstätt M, Länger F, Manns MP, Schulze-Osthoff K et al (2010) Serum biomarkers of cell death for monitoring therapy response of gastrointestinal carcinomas. Eur J Cancer 46:1464-1473
26. Yaman E, Coskun U, Sancak B, Buyukberber S, Ozturk B, Benekli M (2010) Serum M30 levels are associated with survival in advanced gastric carcinoma patients. Int Immunopharmacol 10:719-722
27. Greene FLPD, Fleming ID (2002) American joint committee on cancer staging manual, 6th edn. Springer, Philadelphia
28. Ueno T, Toi M, Bivén K, Bando H, Ogawa T, Linder S (2003) Measurement of an apoptotic product in the sera of breast cancer patients. Eur J Cancer 39:769-774 (Pubitemid 36315993)
29. Bilici A, Ustaalioglu BB, Ercan S, Orcun A, Seker M et al (2011) Is there any impact of plasma M30 and M65 levels on progression-free survival of patients with advanced gastric cancer? Cancer Chemother Pharmacol 68:309-316
30. Demiray M, Ulukaya EE, Arslan M, Gokgoz S, Saraydaroglu O et al (2006) Response to neoadjuvant chemotherapy in breast cancer could be predictable by measuring a novel serum apoptosis product, caspase-cleaved cytokeratin 18: a prospective pilot study. Cancer Invest 24:669-676 (Pubitemid 44836170)
31. Olofsson MH, Ueno T, Pan Y, Xu R, Cai F, van der Kuip H et al (2007) Cytokeratin-18 is a useful serum biomarker for early determination of response of breast carcinomas to chemotherapy. Clin Cancer Res 13:3198-3206 (Pubitemid 46944902)